<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02365571</url>
  </required_header>
  <id_info>
    <org_study_id>15510</org_study_id>
    <secondary_id>I7S-EW-HBEA</secondary_id>
    <nct_id>NCT02365571</nct_id>
  </id_info>
  <brief_title>A Study of LY3154207 in Healthy Participants</brief_title>
  <official_title>Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Cytochrome P450 Interaction Study of LY3154207 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves single doses of LY3154207 and will evaluate the effects of LY3154207 on
      the body. There will be 3 parts to this study.

      Part A will test single increasing doses of LY3154207 and will last approximately 7 weeks for
      each participant. Each participant will receive two doses of LY3154207, if part A is
      completed.

      Part B will test a single dose of LY3154207 and will last approximately 5 weeks for each
      participant. Part B includes collecting fluid from the spinal column to measure levels of
      LY3154207.

      Part C will include a single dose of LY3154207 given alone and then a second dose given along
      with itraconazole to look for change in LY3154207 levels. Part C will last about 3 weeks for
      each participant.

      Participants may only enroll in 1 of the 3 parts of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Up to 48 hours after administration of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) Plasma Part A : Maximum Drug Concentration (Cmax) of LY3154207</measure>
    <time_frame>Predose through 48 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) Plasma Part A: Area Under the Concentration Curve (AUC) of LY3154207</measure>
    <time_frame>Predose through 48 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) Cerebrospinal Fluid (CSF) Part B: Area Under the Concentration Time Curve (AUC) of LY3154207</measure>
    <time_frame>Predose through 48 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) Cerebrospinal Fluid (CSF) Part B: Maximum Drug Concentration (Cmax) of LY3154207</measure>
    <time_frame>Predose through 48 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) Plasma Part C: Area Under the Concentration Time Curve (AUC) of LY3154207 when Co-administered with Itraconazole</measure>
    <time_frame>Predose through 96 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) Plasma Part C: Maximum Drug Concentration (Cmax) of LY3154207 when Co-administered with Itraconazole</measure>
    <time_frame>Predose through 96 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>LY3154207 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3154207 administered in ascending doses once orally in two of three study periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching LY3154207 administered once orally in one of three study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3154207 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3154207 administered once orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching LY3154207 administered once orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3154207 (Part C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3154207 administered once orally on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3154207 + Itraconazole (Part C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Itraconazole administered orally (twice daily on Day 3 and then once daily to Day 12). LY3154207 co-administered once orally, on Day 9. Timing and duration of itraconazole dosing may be adjusted based on data from Part A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3154207</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3154207 (Part A)</arm_group_label>
    <arm_group_label>LY3154207 (Part B)</arm_group_label>
    <arm_group_label>LY3154207 (Part C)</arm_group_label>
    <arm_group_label>LY3154207 + Itraconazole (Part C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_label>Placebo (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Administered orally (twice daily on Day 3 and then once daily to Day 12) as a 10 mg/mL solution</description>
    <arm_group_label>LY3154207 + Itraconazole (Part C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy males or females, as determined by medical history and physical
             examination

          -  Female participants not of child-bearing potential

          -  Are reliable and willing to make themselves available for the duration of the study
             and are willing to follow study procedures

          -  Have given written informed consent

          -  Have a body mass index (BMI) of 18 to 35 kilograms per square meter (kg/m^2)

        Exclusion Criteria:

          -  Part B only: Have medical or surgical conditions in which lumbar puncture is
             contraindicated

          -  Part C only: Have known allergy or contraindications to itraconazole
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1‐877‐CTLILLY (1‐877‐285‐4559) or 1‐317‐615‐4559 Mon ‐ Fri 9 AM ‐ 5 PM Eastern time (UTC/GMT ‐ 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>February 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>June 9, 2015</last_update_submitted>
  <last_update_submitted_qc>June 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

